Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10065006 | 0.89 | SLC22A12 (0.49) | SLC22A12KEAP1NFE2L2MAPTSMN1; SMN2 | |
| SCHEMBL18265852 | 0.86 | SLC22A12 (0.44) | SLC22A12KEAP1NFE2L2MAPTSMN1; SMN2 | |
| SCHEMBL359900 | 0.86 | KEAP1 (0.55) | SLC22A12KEAP1NFE2L2SMN1; SMN2AKR1B1 | |
| SCHEMBL19747685 | 0.86 | SLC22A12 (0.47) | SLC22A12KEAP1NFE2L2MAPTSMN1; SMN2 | |
| SCHEMBL361207 | 0.81 | AKR1B1 (0.54) | AKR1B1 | |
| SCHEMBL8289094 | 0.77 | KEAP1 (0.64) | SLC22A12KEAP1NFE2L2MAPTSMN1; SMN2 | |
| SCHEMBL359954 | 0.77 | AKR1B1 (0.54) | MAPTAKR1B1GABRA1GABRG2GABRB3 | |
| SCHEMBL19194313 | 0.76 | ADRA1A (0.34) | GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL362133 | 0.72 | AKR1B1 (0.54) | AKR1B1 | |
| SCHEMBL360788 | 0.71 | AKR1B1 (0.53) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180907-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-06-06 | — | — | US | disclosed |
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4124620-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-4124620-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2023-02-01 | — | — | EP | disclosed |
| US-11529349-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-20 | — | — | US | disclosed |
| US-11529349-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3597650-B1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20200289512-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-09-17 | — | — | US | disclosed |
| US-20200268755-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-08-27 | — | — | US | disclosed |
| US-9650383-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2593456-B1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20150072989-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-12 | — | — | US | disclosed |
| US-20150072989-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-12 | — | — | US | disclosed |
| US-8916563-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916563-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-29 | — | — | US | disclosed |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-29 | — | — | US | disclosed |
| EP-2593456-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009553-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180907-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SLC22A12 2449/4885KEAP1 80/4885NFE2L2 792/4885 |
| US-20200268755-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SLC22A12 2449/4885KEAP1 80/4885NFE2L2 792/4885 |
| US-20200289512-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SLC22A12 2449/4885KEAP1 80/4885NFE2L2 792/4885 |
| US-11529349-B2 | Aldose reductase inhibitors and uses thereof | ALDOA, AKR1B1, AKR1C2 | SLC22A12 2449/4885KEAP1 80/4885NFE2L2 792/4885 |
| US-20150072989-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SLC22A12 2449/4885KEAP1 80/4885NFE2L2 792/4885 |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SLC22A12 2449/4885KEAP1 80/4885NFE2L2 792/4885 |
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | ALDOA, AKR1B1, AKR1C2 | SLC22A12 2449/4885KEAP1 80/4885NFE2L2 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.